Orphazyme logo — Pioneering therapies to address severe lysosomal storage dis...

Orphazyme

Pioneering therapies to address severe lysosomal storage disorders with roots in groundbreaking academic research from distinguished scientists.

Founded 2009 Post-IPO Equity Total: $883.00M Biotechnology, Health Care +1

General Information

Company Name Orphazyme
Founded Year 2009
Founders / Decision Makers
Team member Team member
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Orphazyme. To contact Orphazyme, visit orphazyme.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Orphazyme compare?

A PDF of Orphazyme and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Orphazyme soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Orphazyme

Orphazyme is a biotechnology startup founded in 2009 with a mission to develop pioneering therapies for severe genetic conditions known as lysosomal storage diseases. The company's roots lie in groundbreaking academic research conducted by its scientific founders, Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse). Based in Copenhagen, Orphazyme has established collaborations with leading academic institutions across Europe and the USA. The company recently secured a kr745.00M investment in post-IPO equity on 7th February 2020. Despite the absence of specific details about the investors, this sizable investment reflects a strong interest and confidence in Orphazyme's innovative approach to addressing severe lysosomal storage disorders. The industries in which Orphazyme operates include Biotechnology, Health Care, and Health and Wellness.

Business keywords: Orphazyme, lysosomal storage disorders, genetic conditions, therapy, academic research, scientific founders, Copenhagen, premier academic institutions, collaborations, innovative therapies, lysosomal storage diseases, discovery, Denmark, USA, Europe

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity kr745.00M -
07 Feb 2020
Venture Round €80.00M 6
Novo Holdings, IDInvest Partners +4
16 Nov 2017
Venture Round €14.00M 7
Novo Holdings, IDInvest Partners +5
08 Mar 2017
Series B $24.00M 4
IDInvest Partners, Kurma Partners +2
09 Jan 2015
Grant Undisclosed 1
Wellcome Trust
17 Sep 2014
Series A $20.00M 3
Novo Holdings, Sunstone Capital +1
07 Sep 2011
Seed Round Undisclosed 2
Novo Holdings, Sunstone Capital
14 Feb 2011

Orphazyme Alternatives & Competitors

View All Alternatives
Orphazyme vs

Perlara is a the first biotech PBC on a mission to codevelop drugs with highly motivated families ra...

Series A
14 employees
Biotechnology, Health and Wellness
Orphazyme vs

Committed to Innovation in Mitochondrial Therapies

Post-IPO Equity
72 employees
Biopharma, Biotechnology
Orphazyme vs
ESCAPE Bio
ESCAPE Bio United States

A CLINICAL-STAGE COMPANY DEVELOPING NOVEL, PRECISELY TARGETED THERAPIES FOR GENETIC NEURODEGENERATIV...

Series B
6 employees
Biotechnology, Health Care

FAQ About Orphazyme

Pioneering therapies to address severe lysosomal storage disorders with roots in groundbreaking academic research from distinguished scientists.
Orphazyme was founded in 2009.
Orphazyme operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Orphazyme, lysosomal storage disorders, genetic conditions and therapy.
Orphazyme has completed 7 funding rounds, raising a total of $883.00M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Orphazyme include Perlara PBC, Stealth BioTherapeutics, ESCAPE Bio, EmendoBio, Alector. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Orphazyme and Perlara PBC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Orphazyme, https://bouncewatch.com/company/orphazyme, updated 27 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes